Back to top
more

Myriad Genetics (MYGN)

(Real Time Quote from BATS)

$5.86 USD

5.86
2,212,192

+0.19 (3.35%)

Updated Aug 7, 2025 01:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks News

Zacks Equity Research

Will Edwards' (EW) Steady Overall Growth Drive Q3 Earnings?

Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q3.

Zacks Equity Research

Can Overall Growth Drive Align Technology (ALGN) Q3 Earnings?

Align Technology (ALGN) likely to gain from strength in Invisalign space as well as Scanner and Service business in Q3.

Zacks Equity Research

Will 5 Elements Drive Quest Diagnostics (DGX) Q3 Earnings?

Quest Diagnostics' (DGX) growing partnerships with health care leaders and strategic acquisitions are expected to boost top and bottom-line growth in Q3.

Zacks Equity Research

Can Solid Overall Growth Drive Illumina (ILMN) Q3 Earnings?

Illumina (ILMN) is likely to gain from strong revenues at the Product, Service and other segments in Q3.

Zacks Equity Research

Company News For Oct 11, 2018

Companies in the news are: CPB, FAST, MYGN, PFE and SHLD

Sweta Jaiswal headshot

Molecular Diagnostic Market Gains Momentum: 3 Stocks in Focus

Rising incidence of infectious diseases and increasing acceptance of companion diagnostics are driving the molecular diagnostics market.

Zacks Equity Research

Myriad (MYGN) Down 0.7% Since Last Earnings Report: Can It Rebound?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Zacks Equity Research

    Company News For Aug 23, 2018

    Companies In The News are: TGT,LOW,NAVG,HIG,MYGN

      Zacks Equity Research

      Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q4

      Myriad Genetics (MYGN) witnesses strong performances from GeneSight, EndoPredict, Vectra DA and Prolaris tests in Q4.

        Zacks Equity Research

        Myriad Genetics (MYGN) Surpasses Q4 Earnings and Revenue Estimates

        Myriad (MYGN) delivered earnings and revenue surprises of 15.15% and 2.63%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

          Zacks Equity Research

          Will Medtronic (MDT) Q1 Earnings Show Overall Progress?

          In Q1, Medtronic (MDT) is expected to have sustained a steady market share across the core pacing, ICD and CRT product lines.

            Zacks Equity Research

            Can Molecular Diagnostics Drive Myriad's (MYGN) Q4 Earnings?

            Myriad (MYGN) likely to deliver solid Q4 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.

              Zacks Equity Research

              Will Myriad (MYGN) Beat Estimates Again in Its Next Earnings Report?

              Myriad (MYGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

                Zacks Equity Research

                Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx

                The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.

                  Zacks Equity Research

                  Why is Myriad Genetics (MYGN) Up 18.6% Since Its Last Earnings Report?

                  Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Sweta Jaiswal headshot

                    Morgan Stanley Calls Labs 'Safe Havens': Stocks to Watch

                    With Morgan Stanley calling clinical laboratory services market a safe haven, let's find out what's working in favor and against this burgeoning niche market.

                      Zacks Equity Research

                      Myriad Genetics' Planned Counsyl Buyout to Widen Portfolio

                      Myriad Genetics (MYGN) plans to retain Counsyl as a wholly-owned subsidiary post the successful completion of the acquisition.

                        Zacks Equity Research

                        Myriad Genetics' Prolaris Expands on New Coverage Decisions

                        This increased rate in commercial insurer coverage for Myriad Genetics' (MYGN) Prolaris comes close on the heels of the NCCN guidelines.

                          Zacks Equity Research

                          Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q3

                          Myriad Genetics' (MYGN) Q3 revenues decline year over year. Strong demand for GeneSight, Vectra DA and Prolaris tests was encouraging.

                            Zacks Equity Research

                            Can Molecular Diagnostics Drive Myriad's (MYGN) Q3 Earnings?

                            Myriad Genetics (MYGN) likely to deliver solid Q3 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.

                              Zacks Equity Research

                              Here's Why You Should Invest in Integer Holdings Right Now

                              Integer Holdings' (ITGR) unswerving focus on customer relationship, cost reduction and burgeoning financial performance are key catalysts.

                                Zacks Equity Research

                                Intuitive Surgical (ISRG) Beats on Q1 Earnings & Revenues

                                Intuitive Surgical's (ISRG) da Vinci platform drives growth in Q1, international sales rise.

                                  Zacks Equity Research

                                  Here's Why You Should Hold on to Cerner (CERN) Stock for Now

                                  Cerner (CERN) gains ground on solid EHR platform, stiff competition raises concern.

                                    Zacks Equity Research

                                    Can MedSurg Business Aid Boston Scientific (BSX) Q1 Earnings?

                                    Boston Scientific's (BSX) MedSurg business is likely to deliver an encouraging show in Q1 on the back of a strong endoscopy, driven by biliary, hemostasis, EndoChoice and Symetis buyouts.

                                      Zacks Equity Research

                                      Can LaunchPad Aid LabCorp's (LH) Covance Arm in Q1 Earnings?

                                      Labcorp's (LH) multi-year LaunchPad project holds enough promise for growth. Good news is that the company already grossed savings worth $20 million from the same in 2017.